Guardant Health Inc. (GH)
NASDAQ
Closed
Oct 9, 2026
Day's Range
166.0352 wk Range
61.00Overview - GH - Guardant Health Inc.
Key Statistics
Valuation
Enterprise Value
24.50B
P/E (Trailing)
‪-53.55‬
P/E (Forward)
‪-446.69‬
PEG Ratio
‪-4.28‬
Price / Sales (TTM)
‪20.16‬
Price / Book
‪-105.99‬
EV / EBITDA
‪-56.91‬
Profitability
Gross Margin
‪65.38%‬
Profit Margin
‪-38.32%‬
Operating Margin
‪-38.24%‬
Return on Assets
‪-18.07%‬
Return on Equity
‪419.18%‬
Ownership
Shares Outstanding
133.61M
Float
129.47M
Short % of Shares Outstanding
‪8.56%‬
Held by Insiders
‪3.96%‬
Held by Institutions
‪100.90%‬
Price stats
Beta
‪1.57‬
50-Day Avg
‪164.78‬
200-Day Avg
‪123.56‬
Dividends
Payout Ratio
‪0.00%‬
Analyst Consensus
26 analysts
Average price target
‪$ 194.29‬Shariah Compliance
Report Date: Feb 20, 2025
Screened by Zoya using the AAOIFI methodology.
Market Cap - GH - Guardant Health Inc.
Peers - GH - Guardant Health Inc.
Peer Comparison
Compared with companies in Diagnostics & Research listed on NASDAQ.
- GHNASDAQGuardant Health Inc.23.86BMarket Cap+64.35%52-week change-53.55P/E (Trailing)‪-38.32%‬Profit Margin
- NTRANASDAQNatera, Inc.59.14BMarket Cap+58.48%52-week change-269.84P/E (Trailing)‪-7.10%‬Profit Margin
- ILMNNASDAQIllumina Inc.41.22BMarket Cap+63.00%52-week change50.85P/E (Trailing)‪18.33%‬Profit Margin
- IDXXNASDAQIDEXX Laboratories, Inc.40.83BMarket Cap-21.10%52-week change37.14P/E (Trailing)‪25.03%‬Profit Margin
- MEDPNASDAQMedpace Holdings, Inc.16.86BMarket Cap+14.16%52-week change35.48P/E (Trailing)‪17.66%‬Profit Margin
- ICLRNASDAQICON plc12.50BMarket Cap-17.51%52-week change170.58P/E (Trailing)‪0.32%‬Profit Margin
- TWSTNASDAQTwist Bioscience Corporation12.12BMarket Cap+85.23%52-week change-140.79P/E (Trailing)‪-31.66%‬Profit Margin
Profile Summary - GH - Guardant Health Inc.
About
Guardant Health Inc. is a precision oncology company that develops blood- and tissue-based tests, data sets, and analytics to support cancer detection and treatment decisions. Its product portfolio includes liquid biopsy tests for tumor mutation profiling, molecular residual disease monitoring, tissue-based genomic…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Shariah compliance data provided by Zoya. Charting by TradingView.
Last updated:
